Outcomes of autologous stem cell transplantation for multiple myeloma in Saudi Arabia.

IF 1.5 4区医学 Q2 MEDICINE, GENERAL & INTERNAL Annals of Saudi Medicine Pub Date : 2021-07-01 Epub Date: 2021-08-22 DOI:10.5144/0256-4947.2021.198

Ahmed Kotb Abdrabou, Fahad Al Sharif, Riad El Fakih, Shahrukh Hashmi, Yasser Mohamed Khafaga, Saud Alhayli, Hazaa Al Zahrani, Syed Ahmed, Feras Al Fraih, Marwan Shaheen, Walid Rasheed, Naeem Arshad Chaudhri, Fahad Al Mohareb, Hala Khalil, Mahmoud Aljurf, Amr Hanbali

{"title":"Outcomes of autologous stem cell transplantation for multiple myeloma in Saudi Arabia.","authors":"Ahmed Kotb Abdrabou, Fahad Al Sharif, Riad El Fakih, Shahrukh Hashmi, Yasser Mohamed Khafaga, Saud Alhayli, Hazaa Al Zahrani, Syed Ahmed, Feras Al Fraih, Marwan Shaheen, Walid Rasheed, Naeem Arshad Chaudhri, Fahad Al Mohareb, Hala Khalil, Mahmoud Aljurf, Amr Hanbali","doi":"10.5144/0256-4947.2021.198","DOIUrl":null,"url":null,"abstract":"Background: In 2015, multiple myeloma (MM) represented 1% of all cancers and about 5% of hematologic malignancies in Saudi cancer registry. We conducted this large study because only small pilot studies have examined MM outcomes after autologous stem-cell transplantation (ASCT). The standard therapy for eligible patients is induction chemotherapy followed by ASCT.Objectives: Determine the demographic characteristics of MM patients and the outcomes of ASCT.Design: Retrospective.Setting: Tumor registry database of major tertiary cancer care center in Riyadh.Patients and methods: We identified patients with newly diagnosed MM who underwent ASCT from October 1997 to March 2015.Main outcome measures: The demographic characteristics of MM patients and the outcomes of ASCT in the form of response evaluation, progression-free survival (PFS) and overall survival (OS).Sample size: 169 patients with newly diagnosed MM.Results: The median age at diagnosis was 51 years (range 23-69) and 100 (59.2%) were male. The most common immunoglobulin (Ig) subtype was IgG-kappa (80 patients; 47.6%). Most patients presented with advanced ISS stage III (75 patients; 47.5%). The cytogenetic analysis was documented in only 87 patients (51.4%); about half (48.3%) had normal cytogenetics by fluorescence in situ hybridization. Deletion 13 was present in 18.4% of patients. In post-induction therapy, 84 patients (50%) achieved a complete response, which increased to 78.1% (132 patients) after ASCT. The median PFS and OS post-transplantation were 30 and 202 months, respectively. Only one patient (<1%) died in the first 100 days after transplantation.Conclusions: Our transplant eligible MM patients tend to be younger with a higher OS and a low ASCT-related mortality (<1%) than is reported internationally.Limitations: Usual limitations of a retrospective analysis using registry-level data; no data on quality of life.Conflicts of interest: None.","PeriodicalId":8016,"journal":{"name":"Annals of Saudi Medicine","volume":"41 4","pages":"198-205"},"PeriodicalIF":1.5000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ff/00/0256-4947.2021.198.PMC8380276.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Saudi Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5144/0256-4947.2021.198","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/8/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 2

Abstract

Background: In 2015, multiple myeloma (MM) represented 1% of all cancers and about 5% of hematologic malignancies in Saudi cancer registry. We conducted this large study because only small pilot studies have examined MM outcomes after autologous stem-cell transplantation (ASCT). The standard therapy for eligible patients is induction chemotherapy followed by ASCT.

Objectives: Determine the demographic characteristics of MM patients and the outcomes of ASCT.

Design: Retrospective.

Setting: Tumor registry database of major tertiary cancer care center in Riyadh.

Patients and methods: We identified patients with newly diagnosed MM who underwent ASCT from October 1997 to March 2015.

Main outcome measures: The demographic characteristics of MM patients and the outcomes of ASCT in the form of response evaluation, progression-free survival (PFS) and overall survival (OS).

Sample size: 169 patients with newly diagnosed MM.

Results: The median age at diagnosis was 51 years (range 23-69) and 100 (59.2%) were male. The most common immunoglobulin (Ig) subtype was IgG-kappa (80 patients; 47.6%). Most patients presented with advanced ISS stage III (75 patients; 47.5%). The cytogenetic analysis was documented in only 87 patients (51.4%); about half (48.3%) had normal cytogenetics by fluorescence in situ hybridization. Deletion 13 was present in 18.4% of patients. In post-induction therapy, 84 patients (50%) achieved a complete response, which increased to 78.1% (132 patients) after ASCT. The median PFS and OS post-transplantation were 30 and 202 months, respectively. Only one patient (<1%) died in the first 100 days after transplantation.

Conclusions: Our transplant eligible MM patients tend to be younger with a higher OS and a low ASCT-related mortality (<1%) than is reported internationally.

Limitations: Usual limitations of a retrospective analysis using registry-level data; no data on quality of life.

Conflicts of interest: None.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

自体干细胞移植治疗多发性骨髓瘤在沙特阿拉伯的结果。

背景:2015年，在沙特癌症登记中，多发性骨髓瘤(MM)占所有癌症的1%，约占血液恶性肿瘤的5%。我们之所以进行这项大型研究，是因为只有小规模的试点研究检查了自体干细胞移植(ASCT)后MM的结果。符合条件的患者的标准治疗是诱导化疗后ASCT。目的:确定MM患者的人口学特征和ASCT的结果。设计:回顾性。设置:利雅得主要三级癌症护理中心的肿瘤登记数据库。患者和方法:我们确定了1997年10月至2015年3月期间接受ASCT的新诊断MM患者。主要结果测量:MM患者的人口学特征和ASCT的结果，以反应评估、无进展生存期(PFS)和总生存期(OS)的形式。结果:诊断时的中位年龄为51岁(范围23-69岁)，男性100例(59.2%)。最常见的免疫球蛋白(Ig)亚型是IgG-kappa(80例;47.6%)。大多数患者表现为晚期ISS III期(75例;47.5%)。仅有87例(51.4%)患者进行了细胞遗传学分析;约半数(48.3%)细胞遗传学正常。18.4%的患者存在13号缺失。在诱导后治疗中，84例(50%)患者获得完全缓解，ASCT后增加到78.1%(132例)。移植后的中位PFS和OS分别为30个月和202个月。结论:符合移植条件的MM患者往往较年轻，OS较高，asct相关死亡率较低(局限性:使用登记级数据进行回顾性分析的通常局限性;没有关于生活质量的数据。利益冲突:无。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Annals of Saudi Medicine 医学-医学：内科

CiteScore

2.80

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： The Annals of Saudi Medicine (ASM) is published bimonthly by King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. We publish scientific reports of clinical interest in English. All submissions are subject to peer review by the editorial board and by reviewers in appropriate specialties. The journal will consider for publication manuscripts from any part of the world, but particularly reports that would be of interest to readers in the Middle East or other parts of Asia and Africa. Please go to the Author Resource Center for additional information.